

RESEARCH

Open Access



Biomarkers for diagnosis of sepsis in patients with systemic inflammatory response syndrome: a systematic review and meta-analysis

Yong Liu^{1†}, Jun-huan Hou^{2,3†}, Qing Li^{2,3}, Kui-jun Chen^{2,3}, Shu-Nan Wang⁴ and Jian-min Wang^{2,3*}

Abstract

Background: Sepsis is one of the most common diseases that seriously threaten human health. Although a large number of markers related to sepsis have been reported in the last two decades, the diagnostic accuracy of these biomarkers remains unclear due to the lack of similar baselines among studies. Therefore, we conducted a large systematic review and meta-analysis to evaluate the diagnostic value of biomarkers from studies that included non-infectious systemic inflammatory response syndrome patients as a control group.

Methods: We searched Medline, Embase and the reference lists of identified studies beginning in April 2014. The last retrieval was updated in September 2016.

Results: Ultimately, 86 articles fulfilled the inclusion criteria. Sixty biomarkers and 10,438 subjects entered the final analysis. The areas under the receiver operating characteristic curves for the 7 most common biomarkers, including procalcitonin, C-reactive protein, interleukin 6, soluble triggering receptor expressed on myeloid cells-1, presepsin, lipopolysaccharide binding protein and CD64, were 0.85, 0.77, 0.79, 0.85, 0.88, 0.71 and 0.96, respectively. The remaining 53 biomarkers exhibited obvious variances in diagnostic value and methodological quality.

Conclusions: Although some biomarkers displayed moderate or above moderate diagnostic value for sepsis, the limitations of the methodological quality and sample size may weaken these findings. Currently, we still lack an ideal biomarker to aid in the diagnosis of sepsis. In the future, biomarkers with better diagnostic value as well as a combined diagnosis using multiple biomarkers are expected to solve the challenge of the diagnosis of sepsis.

Keywords: Biomarkers, Sepsis, Systemic inflammatory response syndrome, Diagnosis, Meta-analysis

Background

Epidemiological surveys indicate that sepsis is the leading cause of non-cardiac death in intensive care units and causes at least 30% of the deaths in patients who are septic (Levy et al. 2010). Along with the aging of the population, the incidence of sepsis shows an obvious increase in countries around the world (Wafaisade et al. 2011; Martin et al. 2003; Angus et al. 2001). An important aspect of

improving survival rates in septic patients is early diagnosis, which is helpful to ensure timely treatment and to avoid deterioration of organ function. The classical method of diagnosis is based on signs of an inflammatory response and microbial cultures. However, doctors must wait for several days before getting culture results, and what is worse, negative culture results account for 30–40%. Because microbial cultures have the features of being time-consuming and having a low positive rate as well as being non-specific for systemic inflammatory response syndrome (SIRS), many patients may lose the opportunity of timely and effective treatment. Unlike microbial culture, biomarkers, primarily from the blood,

*Correspondence: jmwang@tmmu.edu.cn

[†]Yong Liu and Jun-huan Hou contributed equally to this work

²Research Institute of Surgery, Daping Hospital, Third Military Medical University, Chongqing 400042, People's Republic of China

Full list of author information is available at the end of the article

increase in the early stage of the inflammatory response and show different expression between non-infectious inflammation and sepsis. Over the last 20 years, many researchers have been dedicated to finding blood biomarkers for the early diagnosis of infection or sepsis, and they have obtained a substantial number of research results. However, due to the large amounts of experimental data and the inconsistency of the baselines among these studies, it is difficult for medical researchers and workers to make comparisons across various biomarkers or to identify biomarkers with potential diagnostic value. Therefore, we performed a large-scale meta-analysis to summarize potential biomarkers for the differential diagnosis between non-infectious SIRS and sepsis.

Methods

Literature search

We conducted the first systematic retrieval from PubMed and Embase in April 2014. The basic retrieval scheme included the following three search keywords: 'sepsis', 'systemic inflammatory response syndrome' and 'diagnosis'. Then, we excluded 'review', 'erratum', 'editorial' and 'letter' from the retrieval results. In addition, the reference lists of the included original studies and relevant meta-analysis articles were examined for any eligible documents that were missed. The last retrieval was updated in September 2016. The study protocol was approved by the ethics committee affiliated with Daping Hospital and did not require written informed consent from the patients.

Selection criteria

Articles were included if they evaluated the diagnostic accuracy of biomarkers for distinguishing patients with sepsis from those with non-infectious SIRS. Sepsis was defined as the coexistence of SIRS with infection, according to the diagnostic criteria proposed by the American College of Chest Physicians and the Society of Critical Care Medicine (Bone et al. 1992). We excluded articles that lacked non-infectious SIRS patients as a control group. We also eliminated studies with immunocompromised patients, hematologic patients or pediatric patients. Moreover, articles that could not provide sufficient data to build a 2×2 contingency table were likewise excluded.

Data collection and quality assessment

The data were extracted independently by two reviewers (YL and WX) using a pre-designed Microsoft Excel spreadsheet table that included the categories of methodological quality, methods of biomarker detection, features of the participants and results of diagnostic accuracy. If needed, the authors were contacted for any missing


information. We evaluated the quality of the included studies according to the Quality Assessment of Diagnostic Accuracy Studies (QUADAS). Because the analysis of the test results of the biomarkers did not involve clinical data, we omitted item 12 of QUADAS in the quality assessment. Discrepancies between the two reviewers were resolved by discussion with the third author (SHW).

Data synthesis and statistical analysis

The scheme of the systematic review and meta-analysis was implemented in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement (Moher et al. 2010). Stata 13.0 software was used to perform the statistical analysis of the pooled data. We used an exact binomial rendition of the bivariate mixed-effects regression model for the synthesis of diagnostic test data (Reitsma et al. 2005). I^2 statistics were used to reflect the percentage of total variation across articles that were attributable to heterogeneity rather than chance. I^2 values of 25, 50, and 75% describe the heterogeneity as low, moderate, and high, respectively (Higgins et al. 2003). If heterogeneity existed, and the number of studies was larger than 10, the potential reasons for heterogeneity were identified by meta-regression. Publication bias was evaluated by employing a scatter plot with the inverse of the square root of the effective sample size versus the log diagnostic odds ratio, with a symmetrical funnel shape indicating less publication bias (Deeks et al. 2005).

Results

We retrieved articles from the PubMed and EMBASE databases. A total of 31,874 articles remained after duplicates were removed. Three hundred and thirty-two articles were preserved after examining the titles and abstracts. We further excluded 267 articles after reviewing the full content. Sixty-five studies were included in the quantitative synthesis after the first retrieval. Finally, 86 studies were included after two updated searches in February 2015 and September 2016 (Fig. 1) (Abidi et al. 2008; Ahmadinejad et al. 2009; Al-Nawas et al. 1996; Anand et al. 2015; Balc et al. 2003; Barati et al. 2010; Battista et al. 2016; Bell et al. 2003; Beqja-Lika et al. 2013; Carpio et al. 2015; Castelli et al. 2004; Clec'h et al. 2006; de Pablo et al. 2013; Dorizzi et al. 2006; Du et al. 2003; Endo et al. 2012; Farag et al. 2013; Feng et al. 2012; Gaini et al. 2006; Garnacho-Montero et al. 2014; Gerrits et al. 2013; Giamarellos-Bourboulis et al. 2008; Gibot et al. 2004; Godnic et al. 2015; Guven et al. 2002; Han et al. 2016; Harbarth et al. 2001; Hoenigl et al. 2013; Hou et al. 2012, 2016; Hsu et al. 2011; Ishikura et al. 2014; Ivancevic et al. 2008; Jekarl et al. 2013, 2014; Jiang et al. 2015; Kim and Zhang 2012; Kofoed et al. 2007; Latour-Perez et al.



2010; Lewis et al. 2015; Li et al. 2013a; Lin et al. 2015; Matera et al. 2013; Mat-Nor et al. 2016; Mearelli et al. 2014; Meynaar et al. 2011; Miglietta et al. 2015; Miller et al. 1999; Muthiah et al. 2007, Naeini and Montazerolghaem 2006; Oshita et al. 2010; Papadimitriou-Olivergeris et al. 2015; Ratzinger et al. 2013; Reichsoellner et al. 2014; Righi et al. 2014; Rivera-Chavez and Minei 2009; Rogina et al. 2014; Romualdo et al. 2014; Ruiz-Alvarez et al. 2009; Sakr et al. 2008; Scherpereel et al. 2006; Schulte et al.

2011; Selberg et al. 2000; Seok et al. 2012; Shozushima et al. 2011; Sierra et al. 2004; Su et al. 2012, 2013; Sungurtekin et al. 2006; Suprin et al. 2000; Takahashi et al. 2014; Talebi-Taher et al. 2014; Tan et al. 2016; Tian et al. 2014; Tromp et al. 2012; Tsalik et al. 2012; Tsangaris et al. 2009; Tugrul et al. 2002; Ulla et al. 2013; Vaschetto et al. 2008; Vodnik et al. 2013; Wang et al. 2012, 2013; Waner et al. 2000; Xiao et al. 2015; Yousef et al. 2010). The study by Clec’h et al. reported results separately for medical and surgical patients, and the study by Anand et al. reported results for positive and negative cultures. Furthermore, the study by Lin et al. was divided into a training group and validation group. The results of these three studies were divided into six parts (Anand et al. 2015; Clec’h et al. 2006; Lin et al. 2015).

The main characteristics of the studies are shown in Additional file 1: S1. Altogether, 10,438 patients with non-infectious SIRS or sepsis (including 30,043 test instances) and 60 biomarkers were included in the analysis, of which 18,542 instances (61.72%) indicated sepsis, and 11,501 (38.28%) indicated a SIRS of non-infectious origin. The proportion of sepsis among the studies ranged between 16 and 93% (median 61%).

The methodological quality of the included studies was evaluated according to QUADAS. None of the studies fulfilled all of the items. The included studies fulfilled 766 (69%) of the total 1118 items. The quality was poor for item 10 (index test results blinded), item 11 (reference standard results blinded) and item 13 (uninterpretable results) (Additional file 2: S2). Three biomarkers with more than 10 references, including procalcitonin (PCT), C-reactive protein (CRP) and interleukin 6 (IL-6), were evaluated for publication bias by using Deeks’ regression test of asymmetry (Fig. 2). There was significant publication bias for PCT ($P = 0.02$) but not for CRP ($P = 0.62$) and IL-6 ($P = 0.70$).




Table 1 Research results of biomarkers with at least 4 references

Test	Studies	Cut-off	n	TP	FP	FN	TN	AUC (95% CI)	Sensitivity (95% CI)	Specificity (95% CI)
PCT	59	0.96 (0.5, 1.7) ng/ml ^a	7376	3173	847	1060	2296	0.85 [0.82, 0.88]	0.79 [0.75, 0.83]	0.78 [0.74, 0.81]
CRP	45	84 (38, 140) mg/l	5654	2356	719	1014	1565	0.77 [0.73, 0.81]	0.75 [0.69, 0.79]	0.67 [0.58, 0.74]
IL-6	22	138 (75, 220) pg/ml	3450	1376	403	625	1046	0.79 [0.75, 0.82]	0.72 [0.63, 0.80]	0.73 [0.67, 0.79]
sTREM-1	8	123 (635, 594) pg/ml	831	406	82	126	217	0.85 [0.82, 0.88]	0.78 [0.66, 0.87]	0.78 [0.65, 0.87]
Presepsin	9	600 (415, 647) pg/ml	1510	777	155	168	410	0.88 [0.85, 0.90]	0.84 [0.79, 0.88]	0.77 [0.68, 0.84]
LBP	5	30 (24.35, 32) µg/ml	1136	305	208	191	432	0.71 [0.67, 0.75]	0.62 [0.53, 0.71]	0.70 [0.59, 0.79]
CD64	4	–	558	300	13	76	169	0.96 [0.94, 0.97]	0.87 [0.75, 0.94]	0.93 [0.87, 0.96]

TP true positive, FP false positive, FN false negative, TN true negative

^a Median (25% percentiles, 75% percentiles)

Because of there being fewer than 4 references for each, the diagnostic accuracy data of 53 biomarkers could not be pooled by Stata 13.0 software. Thus, we pooled the sensitivity and specificity of 7 biomarkers, including PCT, CRP, IL-6, soluble triggering receptor expressed on myeloid cells-1 (sTREM-1), presepsin (sCD14-ST), lipopolysaccharide binding protein (LBP) and CD64, with 7376, 5654, 3450, 831, 1510, 1136 and 558 participants, respectively, and with the area under the receiver operating characteristic curve (AUC) being 0.85, 0.77, 0.79, 0.85, 0.88, 0.71 and 0.96, respectively (Table 1). The forest plots for the biomarkers are shown in the Additional file 3: S3.

The biomarkers with less than 4 references are displayed in another table (Table 2). Several biomarkers presented high diagnostic values, with AUCs equal to or greater than 0.9 but fewer than 100 participants, including decoy receptor 3 (DcR3), endocan, soluble intercellular adhesion molecule-1 (sICAM-1) and complement 3a (C3a) (with AUCs of 0.96, 0.92, 0.9 and 0.9, respectively).

Except for CD64, the remaining pooled data of 6 biomarkers showed significant heterogeneity. We conducted a meta-regression analysis for 3 biomarkers (PCT, CRP and IL-6) for which the number of studies was larger than 10. Six factors were analyzed as potential sources of heterogeneity, including sample size, publication year, patient age, patient sex, proportion of patients with sepsis and methodological quality. Although the results of the meta-regression analysis showed that the race that was divided into Caucasian and Asian may be the heterogeneity source for PCT and CRP, the heterogeneity did not disappear in subgroup analysis by race. Therefore, there was no one factor that could satisfactorily explain the heterogeneity source of the three biomarkers.

Discussion

A total of 60 types of markers were included in our research. Most of the biomarkers had a small number of references. Six biomarkers with the largest number of participants or studies presented a moderate degree of

diagnostic value, including PCT, CRP, IL-6, presepsin, LBP and sTREM-1, with AUC values of 0.85, 0.77, 0.79, 0.88, 0.71 and 0.85, respectively. Presepsin and sTREM-1, two popular research biomarkers over the last several years, presented diagnostic values similar to PCT. Several biomarkers with AUCs greater than or equal to 0.9 may be potential biomarkers for sepsis, including CD64, DcR3, endocan, sICAM-1 and C3a. However, the biomarkers with the highest AUCs were described in studies with limited sample sizes and inadequate methodological quality.

Although the reference standard for SIRS and sepsis of the included studies was in accordance with the American College of Chest Physicians and the Society of Critical Care Medicine Consensus Conference, most studies did not provide details that described how the patients were diagnosed with SIRS or sepsis. In some studies, only patients with positive cultures were diagnosed with sepsis, while in other studies, all patients with positive cultures or clinically suspected infections were diagnosed with sepsis. We believe that the cohort being investigated should include different types of patients, such as those with positive cultures and those with clinically confirmed infections. Only in this way can the results of the studies be more representative and have more clinical application value. In addition, we believe studies should exclude the patients whose infection status cannot be confirmed, as these patients may lead to selective bias.

We evaluated the publication bias for three biomarkers, PCT, CRP and IL-6. Among them, the funnel plot of PCT presented publication bias. The PCT funnel plot showed a negative correlation between diagnostic value and sample size. In other words, large sample sizes tended to have a relatively small diagnostic value. Although our meta-analysis only searched two databases, PubMed and Embase, our included references and the results of merged data for PCT were similar to the study by Wacker et al. (2013) who searched 7 databases (pooled sensitivity: 0.79 vs. 0.77; pooled specificity: 0.78 vs. 0.79). Therefore, we believe that one of the major reasons for publication

Table 2 The research results for the biomarkers with less than 4 references

Test	References	Cutoff value	N	TP	FP	FN	TN	AUC	Sensitivity	Specificity
<i>Acute phase protein</i>										
AGP	Xiao et al. (2015)	1462 mg/l	277	150	8	42	77	0.869	0.782	0.902
MBL	Ruiz-Alvarez et al. (2009)	–	104	49	13	29	13	0.6	0.63	0.5
SAA	Reichsoellner et al. (2014)	289.4 µg/ml	159	80	32	30	17	0.519	0.73	0.35
sPLA2-IIA	Tan et al. (2016)	2.13 µg/l	51	38	2	4	7	–	0.91	0.78
<i>Biomarkers related to vaosdilation</i>										
Substance P	Reichsoellner et al. (2014)	0.3 ng/ml	159	62	23	48	26	0.524	0.56	0.53
<i>Cell marker biomarkers</i>										
CD64/CD16	Hsu et al. (2011)	–	66	47	2	8	9	0.883	0.855	0.818
CD11C	Lewis et al. (2015)	48.50%	103	67	4	16	16	0.89	0.807	0.8
sCD22	Jiang et al. (2015)	2.3 ng/ml	64	31	6	7	20	–	0.8158	0.7692
sCD163	Feng et al. (2012)	1.49 µg/ml	132	75	2	27	28	0.856	0.74	0.9333
sCD25	Matera et al. (2013)	–	53	25	6	4	18	0.812	0.875	0.75
<i>Coagulation biomarkers</i>										
protein C activity	Ishikura et al. (2014)	47%	82	33	7	10	32	–	0.775	0.811
Thrombomodulin	Reichsoellner et al. (2014)	0 ng/ml	159	30	9	80	40	0.543	0.27	0.81
<i>Cytokine/chemokine biomarkers</i>										
IFN-r	Jekarl et al. (2014)	45 pg/ml	127	68	16	29	14	0.573	0.702	0.464
IFN-r	Matera et al. (2013)	9 pg/ml	52	13	7	15	17	0.486	0.4545	0.7
IL-1	Jekarl et al. (2014)	30 pg/ml	128	38	8	59	23	0.554	0.394	0.75
IL-10	Jekarl et al. (2014)	40 pg/ml	127	32	1	65	29	0.661	0.329	0.964
IL-10	Matera et al. (2013)	3.05 pg/ml	52	22	5	6	19	0.767	0.7826	0.8
IL-10	Reichsoellner et al. (2014)	1.9 ng/ml	159	25	16	85	33	0.508	0.23	0.67
IL-12	Jekarl et al. (2014)	2 pg/ml	127	18	9	79	21	0.504	0.181	0.714
IL-13	Jekarl et al. (2014)	40 pg/ml	128	85	23	12	8	0.508	0.872	0.25
IL-17	Jekarl et al. (2014)	1.5 pg/ml	127	41	9	56	21	0.586	0.426	0.714
IL-2	Jekarl et al. (2014)	35 pg/ml	127	87	24	10	6	0.534	0.894	0.214
IL-2	Balc et al. (2003)	1288.5 pg/ml	83	22	22	13	26	0.641	0.63	0.55
IL22	Jekarl et al. (2014)	300 pg/ml	127	75	18	22	12	0.542	0.776	0.393
IL-4	Jekarl et al. (2014)	25 pg/ml	127	85	24	12	6	0.516	0.872	0.214
IL-5	Jekarl et al. (2014)	5 pg/ml	127	69	9	28	21	0.714	0.713	0.714
IL-8	Balc et al. (2003)	31.5 pg/ml	83	24	21	11	27	0.663	0.68	0.57
IL-8	Harbarth et al. (2001)	30 ng/ml	78	38	4	22	14	0.71	0.63	0.78
IL-8	Reichsoellner et al. (2014)	507.2 pg/ml	160	50	11	61	38	0.625	0.45	0.77
IL-9	Jekarl et al. (2014)	5 pg/ml	128	83	23	14	8	0.532	0.851	0.25
MIF	Kofoed et al. (2007)	0.81 ng/ml	151	77	29	19	26	0.63	0.8	0.47
Osteopontin	Vaschetto et al. (2008)	1.7 ng/ml	56	19	6	8	23	0.796	0.7	0.79
TNF-α	Balc et al. (2003)	11.5 pg/ml	83	19	16	16	32	0.607	0.55	0.66
TNF-α	Jekarl et al. (2014)	15 pg/ml	128	47	8	50	23	0.598	0.489	0.75
TNF-α	Li et al. (2013a, b)	9.75 pg/ml	52	26	4	12	10	0.796	0.68	0.71
<i>Receptor biomarkers</i>										
DcR3	Hou et al. (2012)	2.85 ng/ml	67	23	14	1	29	0.896	0.958	0.674
DcR3	Kim et al. (2012)	3.24 ng/ml	48	24	4	1	19	0.958	0.96	0.826
PLA2-II	Mearelli et al. (2014)	6 ng/ml	80	58	8	2	12	0.851	0.97	0.6
suPAR	Hoeningl et al. (2013)	7.9 ng/ml	132	34	18	21	59	0.726	0.62	0.77
suPAR	Kofoed et al. (2007)	2.7 ng/ml	151	34	18	62	37	0.5	0.35	0.67
suPAR	Reichsoellner et al. (2014)	7.6 ng/ml	160	61	7	50	42	0.66	0.55	0.86
<i>Vascular endothelial biomarkers</i>										
Endocan	Scherpereel et al. (2006)	1.2 ng/ml	70	52	0	11	7	0.923	0.825	1
sICAM-1	de Pablo et al. (2013)	904 ng/ml	92	39	2	13	38	0.9	0.743	0.941

Table 2 continued

Test	References	Cutoff value	N	TP	FP	FN	TN	AUC	Sensitivity	Specificity
<i>Other biomarkers</i>										
Ang 2	Mearelli et al. (2014)	3.2 ng/ml	80	49	12	11	8	0.581	0.82	0.4
Biotin	Reichsoellner et al. (2014)	70.4 pg/ml	159	55	9	55	40	0.646	0.5	0.81
C2	Ruiz-Alvarez et al. (2009)	–	104	6	3	72	23	0.5	0.08	0.9
C3	Sungurtekin et al. (2006)	54 mg/dL	99	25	22	16	36	0.566	0.61	0.625
C3a	Selberg et al. (2000)	540 ng/ml	33	19	2	3	9	0.9	0.86	0.8
C4	Sungurtekin et al. (2006)	28 mg/dL	99	32	36	9	22	0.544	0.78	0.382
cf-DNA	Garnacho-Montero et al. (2014)	2850GE/ml	81	41	20	11	9	0.51	0.7931	0.3023
cf-DNA	Hou et al. (2016)	493 pg/ml	67	23	13	1	30	0.856	0.9412	0.7059
Copeptin	Battista et al. (2016)	23.2 pmol/l	90	47	3	17	23	–	0.74	0.87
Cystatin C	Reichsoellner et al. (2014)	2.1 µg/ml	159	55	14	55	35	0.578	0.5	0.71
Delta neutrophil index	Seok et al. (2012)	0.03%	174	93	1	34	46	0.88	–	–
Elastase	Selberg et al. (2000)	91 µg/ml	33	19	10	3	1	0.57	0.86	0.09
eosinophil	Abidi et al. (2008)	–	140	96	4	24	16	0.84	0.8	0.8
Fibronectin	Reichsoellner et al. (2014)	377.4 µg/ml	159	59	15	51	34	0.384	0.54	0.69
Interferon-induced protein 10	Mearelli et al. (2014)	19.5 ng/ml	80	16	0	44	20	0.666	0.27	1
leptin	Farag et al. (2013)	38.05 ng/ml	30	14	0	1	15	–	–	–
Leptin	Yousef et al. (2010)	38 ng/ml	74	36	5	4	29	–	0.912	0.85
miR-143	Han et al. (2016)	15.9 ng/ml	198	81	8	22	87	–	0.786	0.916
miR-146a	Wang et al. (2013)	–	18	6	1	4	7	0.813	0.6	0.875
miR-15a	Wang et al. (2012)	–	198	113	2	53	30	0.858	0.683	0.944
NGAL	Reichsoellner et al. (2014)	82 ng/ml	159	29	2	81	47	0.599	0.26	0.96
Peroxiredoxin4	Schulte et al. (2011)	4.5 U/l	79	32	7	11	29	0.824	–	–
Thrombocytes	Sungurtekin et al. (2006)	–	99	27	17	14	41	0.656	0.659	0.707

bias in our meta-analysis was more likely the publication of studies with positive or expected results rather than negative results.

Except for CD64, the remaining six biomarkers presented significant heterogeneity. Because the cutoff value for the same biomarker often varied among different studies, the diverse cutoff values often led to the threshold effect as a source of heterogeneity. We used meta-regression analysis to explore the sources of heterogeneity, but no single factor could satisfactorily explain the origins of the heterogeneity, including sample size, publication year, patient age, patient sex, the proportion of patients with sepsis and the methodological quality. Although the heterogeneity among studies was significant, we had stable results for sensitivity analysis. Moreover, the pooled diagnostic test results are consistent with the other meta-analysis results (Wacker et al. 2013; Wu et al. 2012; Li et al. 2013a, b).

Research quality could be an important factor that affected the results. For example, because of limited sample sizes and narrow disease spectra, some studies could not represent the overall state of the patients. In addition, most of the studies did not use blinded methods, which may have resulted in the judgment of sepsis to be affected

by the biomarker determination results. These deficiencies may affect the authenticity of results and also lead to heterogeneity among the studies.

In the review by Pierrakos and Vincent (2010), the researchers retrieved a large number of biomarkers related to sepsis and made a detailed classification of them. However, they did not collect all articles in accordance with the inclusion criteria, nor did they quantitatively evaluate the diagnostic value of biomarkers. Two systematic reviews by Wacker et al. (2013) and Wu et al. (2012) evaluated the diagnostic accuracy of two popular biomarkers to differentiate sepsis from SIRS—PCT and sTREM-1, respectively—but they did not include any other biomarkers. In addition, two other systematic reviews by Simon et al. (2004) and Li et al. (2013b) assessed whether biomarkers could diagnose bacterial infection rather than sepsis. Our review included almost all diagnostic trials for the differential diagnosis of septic patients from those with a SIRS of non-infectious origin published before September 2016. Inconsistent control groups from different studies that may result in heterogeneity were ruled out in our analysis, such as those including healthy individuals, infected patients without SIRS, febrile patients without SIRS and immunocompromised patients. We believed the inconsistency of baselines

among the control groups would lead to incorrect assessments of the diagnostic value of biomarkers.

The biomarker CD64, a cell surface marker, showed a high value for the differential diagnosis of sepsis and SIRS. However, this test requires flow cytometry and trained technical personnel, which limits its feasibility in clinical applications. Obviously, its high cost means that the promotion of one biomarker will be limited in developing or poor countries. Therefore, we believe that a desirable biomarker for diagnosing sepsis should have the following features: high sensitivity and specificity, elevation in the early phase of the infection, low cost and rapid results.

Sepsis is defined as life-threatening organ dysfunction caused by a serious infection, according to a new international expert consensus (Singer et al. 2016). Therefore, SIRS is not a part of the diagnostic criteria of sepsis according to the new guideline. However, previous studies on sepsis markers still have a certain reference value, such as for PCT, which is still widely used in the clinical setting. Summarizing previous research can provide information for new research and guide the development of new studies.

For the objective assessment of the diagnostic value of septic biomarkers, future trials should compare new putative markers with classical biomarkers such as PCT and CRP in the same trial and follow the Standards for Reporting of Diagnostic Accuracy (Bossuyt et al. 2003). Moreover, medical journals should consider accepting more studies with negative or unintended results to avoid publication bias.

The present meta-analysis shows that plasma PCT, sTREM-1 and presepsin have moderate diagnostic utility in differentiating sepsis from SIRS. Several biomarkers with high AUC values, including CD64, DcR3, endocan, sICAM-1 and C3a, need more studies with larger sample sizes and rigorous methodological designs to confirm the results. Not surprisingly, because sepsis is a non-specific clinical syndrome related to serious microorganism infection and uncontrolled immune responses, it is less likely that one biomarker could satisfactorily differentiate sepsis from SIRS patients. In clinical practice, in addition to the dynamic changes of one septic biomarker, doctors should incorporate biomarkers with medical history, clinical symptoms, physical signs and other tests related to infection when diagnosing sepsis. In the future, biomarkers with better diagnostic value and combined diagnosis with multiple biomarkers are expected to solve the challenge of the diagnosis of sepsis.

Additional files

Additional file 1. Characteristics of the included studies.

Additional file 2. The quality assessment of the included studies by QUADAS (Diagnostic Accuracy included in Systematic Reviews).

Additional file 3. Forest plots of biomarkers for the diagnosis of sepsis.

Authors' contributions

QL and JH conceived and designed this study. JW, S-NW and YL were responsible for searching the articles in database. YL and KC were jointly involving in extracting data and writing the manuscript. All authors read and approved the final manuscript.

Author details

¹ Intensive Care Unit, Suining Central Hospital, Deshengxi Road 127, Chuan-shan District, Suining 629000, Sichuan, People's Republic of China. ² Research Institute of Surgery, Daping Hospital, Third Military Medical University, Chongqing 400042, People's Republic of China. ³ State Key Laboratory of Trauma, Burn and Combined Injury, Trauma Center, Chongqing 400042, People's Republic of China. ⁴ Department of Radiology, Institute of Surgery Research, Daping Hospital, Third Military Medical University, Chongqing, People's Republic of China.

Acknowledgements

We thank all the people and patients who participated in this study.

Competing interests

The authors declare that they have no competing interests.

Funding

Funding was provided by Youth Fund of National Natural Science Foundation of China (Grant No. 81401412).

Received: 1 May 2016 Accepted: 20 October 2016

Published online: 12 December 2016

References

- Abidi K, Khoudri I, Belayachi J, Madani N, Zekraoui A, Zeggwagh A et al (2008) Eosinopenia is a reliable marker of sepsis on admission to medical intensive care units. *Crit Care* 12:1
- Ahmadinejad Z, Dadsetan B, Jalili M, Soudbakhsh A, Rasolnejad M (2009) Evaluation of serum procalcitonin in patients with systemic inflammatory response syndrome with and without infection. *Acta Med Iran* 47:383–388
- Al-Nawas B, Krammer I, Shah PM (1996) Procalcitonin in diagnosis of severe infections. *Eur J Med Res* 1:331–333
- Anand D, Das S, Bhargava S, Srivastava LM, Garg A, Tyagi N et al (2015) Procalcitonin as a rapid diagnostic biomarker to differentiate between culture-negative bacterial sepsis and systemic inflammatory response syndrome: a prospective, observational, cohort study. *J Crit Care* 30:218.e7–218.e12
- Angus DC, Linde-Zwirble WT, Lidicker J, Clermont G, Carcillo J, Pinsky MR (2001) Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. *Crit Care Med* 29:1303–1310
- Balc IC, Sungurtekin H, Gurses E, Sungurtekin U, Kaptanoglu B (2003) Usefulness of procalcitonin for diagnosis of sepsis in the intensive care unit. *Crit Care* 7:85–90
- Barati M, Bashar FR, Shahrami R, Zadeh MH, Taher MT, Nojomi M (2010) Soluble triggering receptor expressed on myeloid cells 1 and the diagnosis of sepsis. *J Crit Care* 25:362.e1–362.e6
- Battista S, Audisio U, Galluzzo C, Maggiorotto M, Masoero M, Forno D et al (2016) Assessment of diagnostic and prognostic role of copeptin in the clinical setting of sepsis. *Biomed Res Int* 2016:3624730
- Bell K, Wattie M, Byth K, Silvestrini R, Clark R, Stachowski E et al (2003) Procalcitonin: a marker of bacteraemia is SIRS. *Anaesth Intensive Care* 31:629–636
- Beqja-Lika A, Bullo-Kasneqi A, Refatllari E, Heta-Alliu N, Rucaj-Barbullushi A, Mone I et al (2013) Serum procalcitonine levels as an early diagnostic indicator of sepsis. *Mater Sociomed* 25:23–25
- Bone RC, Balk RA, Cerra FB, Dellinger RP, Fein AM, Knaus WA et al (1992) Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. *Chest* 101:1644–1655

- Bossuyt PM, Reitsma JB, Bruns DE, Gatsonis CA, Glasziou PP, Irwig LM et al (2003) Towards complete and accurate reporting of studies of diagnostic accuracy: the STARD initiative. *BMJ* 326:41–44
- Carpio R, Zapata J, Spanuth E, Hess G (2015) Utility of presepsin (sCD14-ST) as a diagnostic and prognostic marker of sepsis in the emergency department. *Clin Chim Acta* 450:169–175
- Castelli GP, Pognani C, Meisner M, Stuani A, Bellomi D, Sgarbi L (2004) Procalcitonin and C-reactive protein during systemic inflammatory response syndrome, sepsis and organ dysfunction. *Crit Care* 8:R234–R242
- Clec'h C, Fosse JP, Karoubi P, Vincent F, Chouahi I, Hamza L et al (2006) Differential diagnostic value of procalcitonin in surgical and medical patients with septic shock. *Crit Care Med* 34:102–107
- de Pablo R, Monserrat J, Reyes E, Diaz D, Rodriguez-Zapata M, de la Hera A et al (2013) Circulating sICAM-1 and sE-Selectin as biomarker of infection and prognosis in patients with systemic inflammatory response syndrome. *Eur J Intern Med* 24:132–138
- Deeks JJ, Macaskill P, Irwig L (2005) The performance of tests of publication bias and other sample size effects in systematic reviews of diagnostic test accuracy was assessed. *J Clin Epidemiol* 58:882–893
- Dorizzi RM, Polati E, Sette P, Ferrari A, Rizzotti P, Luzzani A (2006) Procalcitonin in the diagnosis of inflammation in intensive care units. *Clin Biochem* 39:1138–1143
- Du B, Pan J, Cheng D, Li Y (2003) Serum procalcitonin and interleukin-6 levels may help to differentiate systemic inflammatory response of infectious and non-infectious origin. *Chin Med J (Engl)* 116:538–542
- Endo S, Suzuki Y, Takahashi G, Shozushima T, Ishikura H, Murai A et al (2012) Usefulness of presepsin in the diagnosis of sepsis in a multicenter prospective study. *J Infect Chemother* 18:891–897
- Farag NA, Taema KM, Abdel-Latif E, Hamed G (2013) Differentiating sepsis from non-infective systemic inflammatory response syndrome: comparison between C-reactive protein and Leptin. *Egypt J Crit Care Med* 1:111–118
- Feng L, Zhou X, Su LX, Feng D, Jia YH, Xie LX (2012) Clinical significance of soluble hemoglobin scavenger receptor CD163 (sCD163) in sepsis, a prospective study. *PLoS ONE* 7:e38400
- Gaini S, Koldkjaer OG, Pedersen C, Pedersen SS (2006) Procalcitonin, lipopolysaccharide-binding protein, interleukin-6 and C-reactive protein in community-acquired infections and sepsis: a prospective study. *Crit Care* 10:R53
- Garnacho-Montero J, Huici-Moreno MJ, Gutierrez-Pizarraya A, Lopez I, Marquez-Vacaro JA, Macher H et al (2014) Prognostic and diagnostic value of eosinopenia, C-reactive protein, procalcitonin, and circulating cell-free DNA in critically ill patients admitted with suspicion of sepsis. *Crit Care* 18:R116
- Gerrits JH, McLaughlin PMJ, Nienhuis BN, Smit JW, Loeff B (2013) Polymorphic mononuclear neutrophils CD64 index for diagnosis of sepsis in postoperative surgical patients and critically ill patients. *Clin Chem Lab Med* 51:897–905
- Giamarellos-Bourboulis EJ, Mouktaroudi M, Tzaganos T, Koutoukas P, Spyridaki E, Pelekanou A et al (2008) Evidence for the participation of soluble triggering receptor expressed on myeloid cells-1 in the systemic inflammatory response syndrome after multiple trauma. *J Trauma* 65:1385–1390
- Gibot S, Kolopp-Sarda MN, Bene MC, Cravoisy A, Levy B, Faure GC et al (2004) Plasma level of a triggering receptor expressed on myeloid cells-1: its diagnostic accuracy in patients with suspected sepsis. *Ann Intern Med* 141:9–15
- Godnic M, Stubljar D, Skvarc M, Jukic T (2015) Diagnostic and prognostic value of sCD14-ST–presepsin for patients admitted to hospital intensive care unit (ICU). *Wien Klin Wochenschr* 127(13):521–527
- Guyen H, Altintop L, Baydin A, Esen S, Aygun D, Hokelek M et al (2002) Diagnostic value of procalcitonin levels as an early indicator of sepsis. *Am J Emerg Med* 20:202–206
- Han Y, Dai QC, Shen HL, Zhang XW et al (2016) Diagnostic value of elevated serum miRNA-143 levels in sepsis. *J Int Med Res* 44(4):875–881
- Harbarth S, Holeckova K, Froidevaux C, Pittet D, Ricou B, Grau GE et al (2001) Diagnostic value of procalcitonin, interleukin-6, and interleukin-8 in critically ill patients admitted with suspected sepsis. *Am J Respir Crit Care Med* 164:396–402
- Higgins JP, Thompson SG, Deeks JJ, Altman DG (2003) Measuring inconsistency in meta-analyses. *BMJ* 327:557–560
- Hoenigl M, Raggam RB, Wagner J, Valentin T, Leitner E, Seeber K et al (2013) Diagnostic accuracy of soluble urokinase plasminogen activator receptor (suPAR) for prediction of bacteremia in patients with systemic inflammatory response syndrome. *Clin Biochem* 46:225–229
- Hou YQ, Xu P, Zhang M, Han D, Peng L, Liang DY et al (2012) Serum decoy receptor 3, a potential new biomarker for sepsis. *Clin Chim Acta* 413:744–748
- Hou YQ, Liang DY, Lou XL, Zhang M, Zhang ZH, Zhang LR (2016) Branched DNA-based Alu quantitative assay for cell-free plasma DNA levels in patients with sepsis or systemic inflammatory response syndrome. *J Crit Care* 31(1):90–95
- Hsu KH, Chan MC, Wang JM, Lin LY, Wu CL (2011) Comparison of Fcγ receptor expression on neutrophils with procalcitonin for the diagnosis of sepsis in critically ill patients. *Respirology* 16:152–160
- Ishikura H, Nishida T, Murai A, Nakamura Y, Irie Y, Tanaka J et al (2014) New diagnostic strategy for sepsis-induced disseminated intravascular coagulation: a prospective single-center observational study. *Crit Care* 18:R19
- Ivancevic N, Radenkovic D, Bumbasirevic V, Karamarkovic A, Jeremic V, Kalezić N et al (2008) Procalcitonin in preoperative diagnosis of abdominal sepsis. *Langenbecks Arch Surg* 393:397–403
- Jekarl DW, Lee SY, Lee J, Park YJ, Kim Y, Park JH et al (2013) Procalcitonin as a diagnostic marker and IL-6 as a prognostic marker for sepsis. *Diagn Microbiol Infect Dis* 75:342–347
- Jekarl DW, Kim JY, Lee S, Kim M, Kim Y, Han K et al (2014) Diagnosis and evaluation of severity of sepsis via the use of biomarkers and profiles of 13 cytokines: a multiplex analysis. *Clin Chem Lab Med* 53:575–581
- Jiang YN, Cai X, Zhou HM, Jin WD, Zhang M, Zhang Y et al (2015) Diagnostic and prognostic roles of soluble CD22 in patients with Gram-negative bacterial sepsis. *Hepatobiliary Pancreat Dis Int* 14(5):523–529
- Kim S, Mi L, Zhang L (2012) Specific elevation of DcR3 in sera of sepsis patients and its potential role as a clinically important biomarker of sepsis. *Diagn Microbiol Infect Dis* 73:312–317
- Kofoed K, Andersen O, Kronborg G, Tvede M, Petersen J, Eugen-Olsen J et al (2007) Use of plasma C-reactive protein, procalcitonin, neutrophils, macrophage migration inhibitory factor, soluble urokinase-type plasminogen activator receptor, and soluble triggering receptor expressed on myeloid cells-1 in combination to diagnose infections: a prospective study. *Crit Care* 11:R38
- Latour-Perez J, Alcalá-Lopez A, García-García MA, Sánchez-Hernández JF, Abad-Terrado C, Viedma-Contreras JA et al (2010) Diagnostic accuracy of sTREM-1 to identify infection in critically ill patients with systemic inflammatory response syndrome. *Clin Biochem* 43:720–724
- Levy MM, Dellinger RP, Townsend SR, Linde-Zwirble WT, Marshall JC, Bion J et al (2010) The Surviving Sepsis Campaign: results of an international guideline-based performance improvement program targeting severe sepsis. *Intensive Care Med* 36:222–231
- Lewis SM, Treacher DF, Edgeworth J, Mahalingam G, Brown CS, Mare TA, Stacey M (2015) Expression of CD11c and EMR2 on neutrophils: potential diagnostic biomarkers for sepsis and systemic inflammation. *Clin Exp Immunol* 182(2):184–194
- Li L, Zhu Z, Chen J, Ouyang B, Chen M, Guan X (2013a) Diagnostic value of soluble triggering receptor expressed on myeloid cells-1 in critically-ill, postoperative patients with suspected sepsis. *Am J Med Sci* 345:178–184
- Li S, Huang X, Chen Z, Zhong H, Peng Q, Deng Y et al (2013b) Neutrophil CD64 expression as a biomarker in the early diagnosis of bacterial infection: a meta-analysis. *Int J Infect Dis* 17:e12–e23
- Lin S, Huang Z, Wang M, Weng Z, Zeng D, Zhang Y et al (2015) Interleukin-6 as an early diagnostic marker for bacterial sepsis in patients with liver cirrhosis. *J Crit Care* 30(4):732–738
- Martin GS, Mannino DM, Eaton S, Moss M (2003) The epidemiology of sepsis in the United States from 1979 through 2000. *N Engl J Med* 348:1546–1554
- Matera G, Puccio R, Giancotti A, Quirino A, Pulicari MC, Zicca E et al (2013) Impact of interleukin-10, soluble CD25 and interleukin-6 on the prognosis and early diagnosis of bacteremic systemic inflammatory response syndrome: a prospective observational study. *Crit Care* 17:R64
- Mat-Nor MB, Md-Ralib A, Abdulah NZ, Pickering JW (2016) The diagnostic ability of procalcitonin and interleukin-6 to differentiate infectious from noninfectious systemic inflammatory response syndrome and to predict mortality. *J Crit Care* 33:245–251
- Mearelli F, Fiotti N, Altamura N, Zanetti M, Fernandes G, Burekovic I et al (2014) Heterogeneous models for an early discrimination between sepsis and non-infective SIRS in medical ward patients: a pilot study. *Intern Emerg Med* 9:749–757

- Meynaar IA, Droog W, Batstra M, Vreede R, Herbrink P (2011) In Critically Ill Patients, Serum Procalcitonin Is More Useful in Differentiating between Sepsis and SIRS than CRP, IL-6, or LBP. *Crit Care Res Pract* 2011:594645
- Miglietta F, Faneschi ML, Lobbreglio G, Palumbo C, Rizzo A, Cucurachi M et al (2015) Procalcitonin, C-reactive protein and serum lactate dehydrogenase in the diagnosis of bacterial sepsis. SIRS and systemic candidiasis. *Infez Med* 23(3):230–237
- Miller PR, Munn DD, Meredith JW, Chang MC (1999) Systemic inflammatory response syndrome in the trauma intensive care unit: who is infected? *J Trauma* 47:1004–1008
- Moher D, Liberati A, Tetzlaff J, Altman DG (2010) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. *Int J Surg* 8:336–341
- Muthiah KA, Rachakonda KS, Davis MJ, Simmons EG, Schier G, Gil FS (2007) Prospective evaluation of procalcitonin in sepsis in the Illawarra area of Australia: PEPSIA study. *Crit Care Resusc* 9:137–142
- Naeini AE, Montazerolghaem S (2006) Procalcitonin marker for sepsis diagnosis. Evaluating a rapid immunochromatographic test. *Saudi Med J* 27:422–424
- Oshita H, Sakurai J, Kamitsuna M (2010) Semi-quantitative procalcitonin test for the diagnosis of bacterial infection: clinical use and experience in Japan. *J Microbiol Immunol Infect* 43:222–227
- Papadimitriou-Olivgeris M, Lekka K, Zisimopoulos K, Spiliopoulou I, Logothetis D, Theodorou G et al (2015) Role of CD64 expression on neutrophils in the diagnosis of sepsis and the prediction of mortality in adult critically ill patients. *Diagn Microbiol Infect Dis* 82(3):234–239
- Pierrakos C, Vincent JL (2010) Sepsis biomarkers: a review. *Crit Care* 14:R15
- Ratzinger F, Schuardt M, Eichbichler K, Tsirkinidou I, Bauer M, Haslachner H et al (2013) Utility of sepsis biomarkers and the infection probability score to discriminate sepsis and systemic inflammatory response syndrome in standard care patients. *PLoS ONE* 8:e82946
- Reichsoellner M, Raggam RB, Wagner J, Krause R, Hoenigl M (2014) Clinical evaluation of multiple inflammation biomarkers for diagnosis and prognosis for patients with systemic inflammatory response syndrome. *J Clin Microbiol* 52:4063–4066
- Reitsma JB, Glas AS, Rutjes AW, Scholten RJ, Bossuyt PM, Zwinderman AH (2005) Bivariate analysis of sensitivity and specificity produces informative summary measures in diagnostic reviews. *J Clin Epidemiol* 58:982–990
- Righi S, Santambrogio L, Monsagrati A, Saliu M, Locati L, Radrizzani D (2014) Clinical evaluation of neutrophil CD64 as a diagnostic marker of infection in a polyvalent intensive care unit. *Infect Dis Clin Pract* 22:32–37
- Rivera-Chavez FA, Minei JP (2009) Soluble triggering receptor expressed on myeloid cells-1 Is an early marker of infection in the surgical intensive care unit. *Surg Infect (Larchmt)* 10:435–439
- Rogina P, Stubljär D, T LZ, Osredkar J, Skvarc M (2014) Expression of CD64 on neutrophils (CD64 index): diagnostic accuracy of CD64 index to predict sepsis in critically ill patients is better than of procalcitonin C-reactive protein, research note. *Clin Chem Lab Med*
- Romualdo LGDG, Torrella PE, Gonzalez MV, Sanchez RJ, Holgado AH, Freire AO et al (2014) Diagnostic accuracy of presepsin (soluble CD14 subtype) for prediction of bacteremia in patients with systemic inflammatory response syndrome in the Emergency Department. *Clin Biochem* 47:505–508
- Ruiz-Alvarez MJ, Garcia-Valdecasas S, De Pablo R, Sanchez Garcia M, Coca C, Groeneveld TW et al (2009) Diagnostic efficacy and prognostic value of serum procalcitonin concentration in patients with suspected sepsis. *J Intensive Care Med* 24:63–71
- Sakr Y, Burgett U, Nacul FE, Reinhart K, Brunckhorst F (2008) Lipopolysaccharide binding protein in a surgical intensive care unit: a marker of sepsis? *Crit Care Med* 36:2014–2022
- Scherpereel A, Depontieu F, Grigoriu B, Cavestri B, Tscopoulos A, Gentina T et al (2006) Endocan, a new endothelial marker in human sepsis. *Crit Care Med* 34:532–537
- Schulte J, Struck J, Kohrle J, Muller B (2011) Circulating levels of peroxiredoxin 4 as a novel biomarker of oxidative stress in patients with sepsis. *Shock* 35:460–465
- Selberg O, Hecker H, Martin M, Klos A, Bautsch W, Kohl J (2000) Discrimination of sepsis and systemic inflammatory response syndrome by determination of circulating plasma concentrations of procalcitonin, protein complement 3a, and interleukin-6. *Crit Care Med* 28:2793–2798
- Seok Y, Choi JR, Kim J, Kim YK, Lee J, Song J et al (2012) Delta neutrophil index: a promising diagnostic and prognostic marker for sepsis. *Shock* 37:242–246
- Shozushima T, Takahashi G, Matsumoto N, Kojika M, Okamura Y, Endo S (2011) Usefulness of presepsin (sCD14-ST) measurements as a marker for the diagnosis and severity of sepsis that satisfied diagnostic criteria of systemic inflammatory response syndrome. *J Infect Chemother* 17:764–769
- Sierra R, Rello J, Bailen MA, Benitez E, Gordillo A, Leon C et al (2004) C-reactive protein used as an early indicator of infection in patients with systemic inflammatory response syndrome. *Intensive Care Med* 30:2038–2045
- Simon L, Gauvin F, Amre DK, Saint-Louis P, Lacroix J (2004) Serum procalcitonin and C-reactive protein levels as markers of bacterial infection: a systematic review and meta-analysis. *Clin Infect Dis* 39:206–217
- Singer M, Deutschman CS, Seymour CW, Shankar-Hari M, Annane D, Bauer M et al (2016) The third international consensus definitions for sepsis and septic shock (sepsis-3). *JAMA* 315(8):801–810
- Su L, Han B, Liu C, Liang L, Jiang Z, Deng J et al (2012) Value of soluble TREM-1, procalcitonin, and C-reactive protein serum levels as biomarkers for detecting bacteremia among sepsis patients with new fever in intensive care units: a prospective cohort study. *BMC Infect Dis* 12:157
- Su L, Feng L, Song Q, Kang H, Zhang X, Liang Z et al (2013) Diagnostic value of dynamics serum sCD163, sTREM-1, PCT, and CRP in differentiating sepsis, severity assessment, and prognostic prediction. *Mediators Inflamm* 2013:969875
- Sungurtekin H, Sungurtekin U, Balci C (2006) Circulating complement (C3 and C4) for differentiation of SIRS from sepsis. *Adv Ther* 23:893–901
- Suprin E, Camus C, Gacouin A, Le Tulzo Y, Lavoue S, Feuillu A et al (2000) Procalcitonin: a valuable indicator of infection in a medical ICU? *Intensive Care Med* 26:1232–1238
- Takahashi G, Shibata S, Ishikura H, Miura M, Fukui Y, Inoue Y et al (2014) Presepsin in the prognosis of infectious diseases and diagnosis of infectious disseminated intravascular coagulation: a prospective, multicentre, observational study. *Eur J Anaesthesiol*
- Talebi-Taher M, Babazadeh S, Barati M, Latifnia M (2014) Serum inflammatory markers in the elderly: are they useful in differentiating sepsis from SIRS? *Acta Med Iran* 52:438–442
- Tan TL, Ahmad NS, Nasuruddin DN, Ithnin A, Tajul Arifin K, Zaini IZ et al (2016) CD64 and Group II secretory phospholipase A2 (sPLA2-IIA) as biomarkers for distinguishing adult sepsis and bacterial infections in the emergency department. *PLoS ONE* 11(3):e0152065
- Tian G, Pan S, Ma G, Liao W, Su Q, Gu B et al (2014) Serum levels of procalcitonin as a biomarker for differentiating between sepsis and systemic inflammatory response syndrome in the neurological intensive care unit. *J Clin Neurosci* 21:1153–1158
- Tromp M, Lansdorp B, Bleeker-Rovers CP, Gunnewiek JM, Kullberg BJ, Pickkers P (2012) Serial and panel analyses of biomarkers do not improve the prediction of bacteremia compared to one procalcitonin measurement. *J Infect* 65:292–301
- Tsaliik EL, Jagers LB, Glickman SW, Langley RJ, van Velkinburgh JC, Park LP et al (2012) Discriminative value of inflammatory biomarkers for suspected sepsis. *J Emerg Med* 43:97–106
- Tsangaris I, Plachouras D, Kavatha D, Gourgoulis GM, Tsantes A, Kopterides P et al (2009) Diagnostic and prognostic value of procalcitonin among febrile critically ill patients with prolonged ICU stay. *BMC Infect Dis* 9:213
- Tugrul S, Esen F, Celebi S, Ozcan PE, Akinci O, Cakar N et al (2002) Reliability of procalcitonin as a severity marker in critically ill patients with inflammatory response. *Anaesth Intensive Care* 30:747–754
- Ulla M, Pizzolato E, Lucchiari M, Loiacono M, Soardo F, Forno D et al (2013) Diagnostic and prognostic value of presepsin in the management of sepsis in the emergency department: a multicenter prospective study. *Crit Care* 17:R168
- Vaschetto R, Nicola S, Olivieri C, Boggio E, Piccolella F, Mesturini R et al (2008) Serum levels of osteopontin are increased in SIRS and sepsis. *Intensive Care Med* 34:2176–2184
- Vodnik T, Kaljevic G, Tadic T, Majkic-Singh N (2013) Presepsin (sCD14-ST) in preoperative diagnosis of abdominal sepsis. *Clin Chem Lab Med* 51:2053–2062

- Wacker C, Prkno A, Brunkhorst FM, Schlattmann P (2013) Procalcitonin as a diagnostic marker for sepsis: a systematic review and meta-analysis. *Lancet Infect Dis* 13:426–435
- Wafaisade A, Lefering R, Bouillon B, Sakka SG, Thamm OC, Paffrath T et al (2011) Epidemiology and risk factors of sepsis after multiple trauma: an analysis of 29,829 patients from the Trauma Registry of the German Society for Trauma Surgery. *Crit Care Med* 39:621–628
- Wang H, Zhang P, Chen W, Feng D, Jia Y, Xie LX (2012) Evidence for serum miR-15a and miR-16 levels as biomarkers that distinguish sepsis from systemic inflammatory response syndrome in human subjects. *Clin Chem Lab Med* 50:1423–1428
- Wang L, Wang HC, Chen C, Zeng J, Wang Q, Zheng L et al (2013) Differential expression of plasma miR-146a in sepsis patients compared with non-sepsis-SIRS patients. *Exp Ther Med* 5:1101–1104
- Wanner GA, Keel M, Steckholzer U, Beier W, Stocker R, Ertel W (2000) Relationship between procalcitonin plasma levels and severity of injury, sepsis, organ failure, and mortality in injured patients. *Crit Care Med* 28:950–957
- Wu Y, Wang F, Fan X, Bao R, Bo L, Li J et al (2012) Accuracy of plasma sTREM-1 for sepsis diagnosis in systemic inflammatory patients: a systematic review and meta-analysis. *Crit Care* 16:R229
- Xiao K, Su L, Yan P, Han B, Li J, Wang H et al (2015) alpha-1-Acid glycoprotein as a biomarker for the early diagnosis and monitoring the prognosis of sepsis. *J Crit Care* 30(4):744–751
- Yousef AA, Amr YM, Suliman GA (2010) The diagnostic value of serum leptin monitoring and its correlation with tumor necrosis factor-alpha in critically ill patients: a prospective observational study. *Crit Care* 14:R33

Submit your manuscript to a SpringerOpen[®] journal and benefit from:

- Convenient online submission
- Rigorous peer review
- Immediate publication on acceptance
- Open access: articles freely available online
- High visibility within the field
- Retaining the copyright to your article

Submit your next manuscript at ► springeropen.com
